/PRNewswire/ In the near future, the antimicrobial resistance surveillance industry is poised to undergo a transformative evolution, driven by advances in.
Accelerate Diagnostics, Inc. (NASDAQ:AXDX – Free Report) – Equities researchers at William Blair boosted their Q3 2023 earnings per share estimates for Accelerate Diagnostics in a research report issued to clients and investors on Monday, August 14th. William Blair analyst A. Brackmann now forecasts that the medical research company will earn ($0.94) per share for […]
Accelerate Diagnostics, Inc. (NASDAQ:AXDX – Get Free Report) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 437,400 shares, a growth of 8.4% from the July 15th total of 403,500 shares. Based on an average daily trading volume, of 27,500 […]